No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Medical - Distribution
DocMorris AG is a key player in the pharmaceutical sector, focusing on both online pharmacy services and the wholesale supply of medical and pharmaceutical goods. The company provides a comprehensive selection of items, including prescription and over-the-counter medications, health and wellness products, beauty and personal care lines, dietary supplements, pain relief remedies, and emergency first aid supplies. Furthermore, it offers specialized medication management support. In addition to its significant digital footprint, DocMorris AG also operates traditional brick-and-mortar pharmacy locations. Its commercial activities extend across Switzerland and into various international territories, serving medical practitioners, other online pharmaceutical distributors, and individual consumers directly. Notable brands within its portfolio include Zur Rose, PromoFarma, TeleClinic, and DocMorris. Established in 1993 and based in Frauenfeld, Switzerland, the company adopted its current name, DocMorris AG, in May 2023, having previously been known as Zur Rose Group AG.
corporate.docmorris.com/enNo one on the platform currently holds DOCM.SW.
No tracked institution reports a position in DOCM.SW as of their last filing.
No one on the platform has traded DOCM.SW yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | — | — | — | |||
| Rev. Growth % | 10.6% | -5.3% | ||||
| Profit Margin % | -12.0% | -8.9% | -6.6% | |||
| Free Cash Flow Margin % | -8.0% | -10.7% | -8.5% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $1.3B | +12.4% | $-1.69 | $-2.47–$-1.25 | — | 5 |
| 2027 | $1.4B | +11.2% | $-0.85 | $-1.50–$-0.61 | — | 5 |
| 2028 | $1.5B | +10.2% | $-0.25 | $-0.91–$0.79 | — | 5 |
| 2029 | $1.8B | +14.7% | $0.30 | $0.29–$0.31 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 3 of the last 5 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-08-19 | $-3.71 | $-1.10 | +70.3% |
| 2025-05-08 | $-2.27 | $-2.47 | -9.0% |
| 2025-03-13 | $-2.55 | $-1.59 | +37.8% |
| 2024-08-20 | $-2.55 | $-1.59 | +37.8% |
| 2023-10-19 | $-0.52 | $-2.46 | -376.7% |
| $15M |
| — |
| MOLN.SWMolecular Partners AG | $3.27 | -1.80% | $123M | — |
| NWRN.SWNewron Pharmaceuticals S.p.A. | $11.06 | -2.47% | $230M | — |
Source: Financial Modeling Prep · peers by sector/industry